Prolactin receptor antagonist - Oncolix
Alternative Names: ProlantaLatest Information Update: 28 Dec 2019
Price :
$50 *
At a glance
- Originator Oncolix
- Class Hormones; Pituitary gonadotropins
- Mechanism of Action Prolactin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Recurrent, Second-line therapy or greater) in USA (SC)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Ovarian-cancer(Recurrent, Second-line therapy or greater) in USA (SC)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Peritoneal-cancer(Recurrent, Second-line therapy or greater) in USA (SC)